Type 2 diabetes mellitus (T2DM) is one of the most concerning chronic diseases in adults, and its incidence in children and adolescents has increased dramatically over the past 20 years. However, pharmacotherapy options for pediatric T2DM have been limited compared with those for adults. Metformin was approved for use in youth in 2000 and is currently the first-line noninsulin treatment for pediatric T2DM. In 2019, liraglutide was approved for use in youth aged 10 years or older, making it the first noninsulin medication approved for children and adolescents since the approval of metformin. Liraglutide is a glucagon like peptide-1 (GLP-1) receptor agonist. It regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion and is also indicated to reduce cardiovascular risk in patients with T2DM. With new treatment options such as these available, there is a need for evidence on pharmacotherapy of pediatric T2DM to inform clinical practice, policy making, and future research directions in the management of T2DM in children and adolescents.
The goal of this Research Topic is to summarize studies on the utilization, effectiveness, and safety of pharmacological treatment for T2DM among children and adolescents. We aim to provide the state of evidence of patterns of utilization of various T2DM pharmacotherapy options, comparative effectiveness of different treatment strategies, and short-/long-term health outcomes in the population. This Research Topic will also help advance the paradigms of generating and utilizing real-world evidence that bridges pharmaceutical sciences, clinical pharmacology and pharmacoepidemiology.
We welcome original research and review articles addressing the above goal. Research that evaluates population health outcomes using pharmacoepidemiology data, examines treatment efficacy and related adverse events using clinical data, and describes medication utilization patterns are specifically encouraged.
Type 2 diabetes mellitus (T2DM) is one of the most concerning chronic diseases in adults, and its incidence in children and adolescents has increased dramatically over the past 20 years. However, pharmacotherapy options for pediatric T2DM have been limited compared with those for adults. Metformin was approved for use in youth in 2000 and is currently the first-line noninsulin treatment for pediatric T2DM. In 2019, liraglutide was approved for use in youth aged 10 years or older, making it the first noninsulin medication approved for children and adolescents since the approval of metformin. Liraglutide is a glucagon like peptide-1 (GLP-1) receptor agonist. It regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion and is also indicated to reduce cardiovascular risk in patients with T2DM. With new treatment options such as these available, there is a need for evidence on pharmacotherapy of pediatric T2DM to inform clinical practice, policy making, and future research directions in the management of T2DM in children and adolescents.
The goal of this Research Topic is to summarize studies on the utilization, effectiveness, and safety of pharmacological treatment for T2DM among children and adolescents. We aim to provide the state of evidence of patterns of utilization of various T2DM pharmacotherapy options, comparative effectiveness of different treatment strategies, and short-/long-term health outcomes in the population. This Research Topic will also help advance the paradigms of generating and utilizing real-world evidence that bridges pharmaceutical sciences, clinical pharmacology and pharmacoepidemiology.
We welcome original research and review articles addressing the above goal. Research that evaluates population health outcomes using pharmacoepidemiology data, examines treatment efficacy and related adverse events using clinical data, and describes medication utilization patterns are specifically encouraged.